MedPath

High Pasta vs. Low Pasta Diet in the Treatment of Obesity

Not Applicable
Completed
Conditions
Diet Therapy
Interventions
Behavioral: Low Pasta
Behavioral: High Pasta
Registration Number
NCT03341650
Lead Sponsor
University of Parma
Brief Summary

To the best of our knowledge, the effect of pasta consumption within a hypocaloric Mediterranean diet has only been scarcely explored yet. Therefore, a two-parallel group dietary intervention was carried out to investigate if pasta consumption could affect the BMI change in obese patients. The primary outcome was the loss of at leat 8% of the initial body weight in the first 6 months. Anthropometric and body composition (from bioelectrical impedance analysis - BIA-) measures were collected every month for the first 6 months and after 1 year. In addition, dietary information was collected at baseline and after 3, 6 and 12 months through a 7-day carbohydrate food record and a 24-h food recall. Blood samples were collected at baseline and at 6 and 12 months to assess: glucose, insulin, Homeostatic model assessment for insulin resistant (HOMA-IR) index, total cholesterol, low-density lipoprotein, high-density lipoprotein, and uric acid. Furthermore, the perceived quality of life was investigated through the 36-items short form health survey (SF36) questionnaire.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • BMI between 30-45 kg/m2
  • healthy subjects
  • regular meal consumption
  • no celiac disease
  • no menopause woman
Exclusion Criteria
  • with a BMI <30 or >45 kg/m2
  • having diabetes, hepatic or kidney diseases
  • having an eating disorder
  • having celiac disease
  • menopause woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Low PastaLow PastaHabitual pasta consumption equal or lower than 3 times/week.
High PastaHigh PastaHabitual pasta consumption equal or higher than 5 times/week.
Primary Outcome Measures
NameTimeMethod
Change from baseline Body weight at 6 monthsbaseline, 6 months

Measured in kg according to the standard procedure

Secondary Outcome Measures
NameTimeMethod
Waist circumferencebaseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months

Measured in cm according to the standard procedure

Glucosebaseline, 6 months, 12 months

mg/dL in fasting condition

Change from baseline Body weight at 3 monthsbaseline, 3 months

Measured in kg according to the standard procedure

Change from baseline Body weight at 12 monthsbaseline, 12 months

Measured in kg according to the standard procedure

Fat Massbaseline, 3 months, 6 months, 12 months

Estimated by bioelectrical impedance analysis in kg and in %

Basal Metabolic Ratebaseline, 3 months, 6 months, 12 months

Estimated by bioelectrical impedance analysis in kcal/day

HOMA-IR indexbaseline, 6 months, 12 months

calculated from glucose and insulin in fasting condition

HDL cholesterolbaseline, 6 months, 12 months

mg/dL in fasting condition

Energy intakebaseline, 3 months, 6 months, 12 months

assessed by a 24-h dietary recall as kcal/day

Nutrient intakesbaseline, 3 months, 6 months, 12 months

assessed by a 24-h dietary recall as g/day

Carbohydrate-based food intakesbaseline, 3 months, 6 months, 12 months

assessed by a 7-day food diary as times/week

Triglyceridesbaseline, 6 months, 12 months

mg/dL in fasting condition

Insulinbaseline, 6 months, 12 months

microU/mL in fasting condition

Total cholesterolbaseline, 6 months, 12 months

mg/dL in fasting condition

Perceived Quality of Lifebaseline, 3 months, 6 months, 12 months

assessed by the SF36 questionnaire

BMIbaseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months

Calculated as body weight in kilograms divided by the square of the height in meters

Free Fat Massbaseline, 3 months, 6 months, 12 months

Estimated by bioelectrical impedance analysis in kg and in %

LDL cholesterolbaseline, 6 months, 12 months

mg/dL in fasting condition

Uric Acidbaseline, 6 months, 12 months

mg/dL in fasting condition

Trial Locations

Locations (1)

Department of Food and Drug, University of Parma

🇮🇹

Parma, Italy

© Copyright 2025. All Rights Reserved by MedPath